Green Light For Janssen’s Canagliflozin In India
This article was originally published in PharmAsia News
The Indian regulator has cleared Janssen’s canagliflozin for marketing in India after a review process that lasted more than a year. Experts say commercial success of the SGLT-2 inhibitor will hinge on an appropriate pricing strategy and a wide disease management network. Closing in soon on canagliflozin are two other drugs – dapagliflozin and empagliflozin.